Publications by authors named "Gary Meininger"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

42,405

Total Likes

775

Extended Reach

1,347,049

Social Features

221
A
Acute pancreatitis risk in type 2 diabetes patients treated with canagliflozin versus other antihyperglycemic agents: an observational claims database study.
Zhong Yuan, Frank DeFalco, Lu Wang, Laura Hester, James Weaver, Gary Meininger

Curr Med Res Opin· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases.
Lu Wang, Erica A Voss, James Weaver, Laura Hester, Zhong Yuan, Gary Meininger

Pharmacoepidemiol Drug Saf· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors influencing longitudinal changes of circulating liver enzyme concentrations in subjects randomized to placebo in four clinical trials.
Derek J Nunez, Myriam Alexander, Laura Yerges-Armstrong, Gurparkash Singh, Geert Byttebier, Gary Meininger

Am J Physiol Gastrointest Liver Physiol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Achieving the composite endpoint of HbA1c, body weight, and systolic blood pressure reduction with canagliflozin in patients with type 2 diabetes.
Katherine Merton, Michael J Davies, Ujjwala Vijapurkar, Doreen Inman, Gary Meininger

Curr Med Res Opin· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis.
Rong Qiu, Dainius Balis, John Xie, Michael J Davies, Mehul Desai, Gary Meininger

Curr Med Res Opin· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial.
Bruce Neal, Vlado Perkovic, David R Matthews, Kenneth W Mahaffey, Greg Fulcher, Gary Meininger

Diabetes Obes Metab· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects.
Hiddo J L Heerspink, Mehul Desai, Meg Jardine, Dainius Balis, Gary Meininger

J Am Soc Nephrol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Canagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 Diabetes.
Rong Qiu, Dainius Balis, George Capuano, John Xie, Gary Meininger

Diabetes Ther· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures.
Charmi A Patel, Robert A Bailey, Ujjwala Vijapurkar, Gary Meininger, Lawrence Blonde

BMC Health Serv Res· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Age and Estimated Glomerular Filtration Rate on the Glycemic Efficacy and Safety of Canagliflozin: A Pooled Analysis of Clinical Studies.
Richard E Gilbert, Matthew R Weir, Paola Fioretto, Gordon Law, Mehul Desai, Gary Meininger

Can J Diabetes· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus.
James R Gavin, Melanie J Davies, Michael Davies, Ujjwala Vijapurkar, Maria Alba, Gary Meininger

Curr Med Res Opin· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks.
Lawrence Blonde, Kaj Stenlöf, Albert Fung, John Xie, William Canovatchel, Gary Meininger

Postgrad Med· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from India.
K M Prasanna Kumar, Viswanathan Mohan, Bipin Sethi, Pramod Gandhi, Ganapathi Bantwal, Gary Meininger

Indian J Endocrinol Metab· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Canagliflozin in Type 2 Diabetes Patients of Different Ethnicity.
Jaime A Davidson, Richard Aguilar, Fernando J Lavalle González, Angelina Trujillo, Maria Alba, Gary Meininger

Ethn Dis· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis.
Alan J Sinclair, Bruce Bode, Stewart Harris, Ujjwala Vijapurkar, Wayne Shaw, Gary Meininger

J Am Geriatr Soc· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus.
Nelson B Watts, John P Bilezikian, Keith Usiskin, Robert Edwards, Mehul Desai, Gary Meininger

J Clin Endocrinol Metab· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to Comment on Erondu et al. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care 2015;38:1680-1686.
Ngozi Erondu, Mehul Desai, Kirk Ways, Gary Meininger

Diabetes Care· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Renal effects of canagliflozin in type 2 diabetes mellitus.
Vlado Perkovic, Meg Jardine, Ujjwala Vijapurkar, Gary Meininger

Curr Med Res Opin· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
Norm Rosenthal, Gary Meininger, Kirk Ways, David Polidori, Mehul Desai

Ann N Y Acad Sci· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Achievement of treatment goals with canagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of randomized controlled trials.
Lawrence Blonde, Vincent Woo, Chantal Mathieu, Jacqueline Yee, Ujjwala Vijapurkar, Gary Meininger

Curr Med Res Opin· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial.
Greg Fulcher, David R Matthews, Vlado Perkovic, Dick de Zeeuw, Kenneth W Mahaffey, Gary Meininger

Diabetes Ther· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program.
Ngozi Erondu, Mehul Desai, Kirk Ways, Gary Meininger

Diabetes Care· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes.
William T Cefalu, Kaj Stenlöf, Lawrence A Leiter, John P H Wilding, Lawrence Blonde, Gary Meininger

Diabetologia· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diabetes-Related Composite Quality End Point Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials.
Robert A Bailey, Ujjwala Vijapurkar, Gary Meininger, Marcia F T Rupnow, Lawrence Blonde

Clin Ther· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis